Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment

Pharmacopsychiatry

Volumn 44, Issue 3, 2011, Pages 96-101

  Verdoux, H ^a,b,c   Cougnard, A ^a,b   Thiebaut A ^b   Tournier, M ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM U657   (France)

^c CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; DATA BASE; FEMALE; FOLLOW UP; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; SENSITIVITY ANALYSIS; TREATMENT DURATION;

EID: 79956064767     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1271686     Document Type: Article

References (28)

1. Bauer M, Bschor T, Pfennig A et al,. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007 8 67-104 (Pubitemid 46690921)
2. Anderson IM, Ferrier IN, Baldwin RC et al,. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 22 343-396 (Pubitemid 351989984)
3. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (update). (Clinical guideline 90) http://guidance.nice.org.uk/CG90 2009
4. Geddes JR, Carney SM, Davies C et al,. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003 361 653-661 (Pubitemid 36246547)
5. Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010 340 752-756
6. Tournier M, Cougnard A, Boutouaba-Combe S et al,. Duration of antidepressant drug treatment and its determinants in France [in French]. Encephale 2010 In press
7. Olfson M, Marcus SC, Tedeschi M et al,. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006 163 101-108 (Pubitemid 43050110)
8. Melfi CA, Chawla AJ, Croghan TW et al,. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998 55 1128-1132 (Pubitemid 28558286)
9. Sood N, Treglia M, Obenchain RL et al,. Determinants of antidepressant treatment outcome. Am J Managed Care 2000 6 1327-1336 (Pubitemid 32043656)
10. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Brit J Psychiatry 2000 177 163-168 (Pubitemid 30624829)
11. Gardarsdottir H, van Geffen EC, Stolker JJ et al,. Does the length of the first antidepressant treatment episode influence risk and time to a second episode? J Clin Psychopharmacol 2009 29 69-72
12. Kirsch I, Deacon BJ, Huedo-Medina TB et al,. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 5 e45
13. Fournier JC, DeRubeis RJ, Hollon SD et al,. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010 303 47-53
14. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 2010 19 256-265
15. De Roquefeuil L, Studer A, Neumann A et al,. LEchantillon généraliste de bénéficiaires: repré sentativité, portée et limites. [in French]. Pratiques et Organisations de Soins 2009 40 213-223
16. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. Oslo, Norway, Norwegian Institute of Public Health 2007
17. StataCorp. Stata Statistical Software: Release 9.0. College Station, Texas, Stata Corporation 2005
18. Hertz-Picciotto I, Rockhill B. Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics 1997 53 1151-1156 (Pubitemid 27391042)
19. Gardarsdottir H, Egberts TC, Stolker JJ et al,. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. Am J Epidemiol 2009 170 280-285
20. Gardarsdottir H, Egberts AC, Heerdink ER. Transitions from general practitioner to psychiatrist care (or vice versa) during a first antidepressant treatment episode. Pharmacopsychiatry 2010 43 179-183
21. Gardarsdottir H, Souverein PC, Egberts TC et al,. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 2010 63 422-427
22. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev 2007 27 959-985 (Pubitemid 47600441)
23. Moller HJ, Schnitker J, Flurenbrock W. Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. Pharmacopsychiatry 2010 43 210-215
24. Grolleau A, Cougnard A, Begaud B et al,. Congruence between diagnosis of recurrent major depressive disorder and psychotropic treatment in the general population. Acta Psychiatr Scand 2008 117 20-27 (Pubitemid 350256540)
25. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009 374 609-619
26. Kessler RC, Berglund P, Demler O et al,. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 289 3095-3105 (Pubitemid 37432885)
27. Druss BG, Wang PS, Sampson NA et al,. Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007 64 1196-1203 (Pubitemid 47529344)
28. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004 292 338-343 (Pubitemid 38944257)